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The novel, highly contagious coronavirus SARS-CoV-2 spreads rapidly throughout
the world, leading to a deadly pandemic of a predominantly respiratory illness
called COVID-19. Safe and effective anti-SARS-CoV-2 vaccines are urgently
needed. However, emerging immunological observations show hallmarks of significant
immunopathological characteristics and dysfunctional immune responses in patients
with COVID-19. Combined with existing knowledge about immune responses to other
closely related and highly pathogenic coronaviruses, this could forebode significant
challenges for vaccine development, including the risk of vaccine failure. Animal data
from earlier coronavirus vaccine efforts indicate that elderly people, most at risk from
severe COVID-19 disease, could be especially at risk from immunopathologic responses
to novel coronavirus vaccines. Bacterial “new old friends” such as Bacille Calmette-
Guérin (BCG) or Mycobacterium obuense have the ability to elevate basal systemic
levels of type 1 cytokines and immune cells, correlating with increased protection against
diverse and unrelated infectious agents, called “trained immunity.” Here we describe
dysfunctional immune responses induced by coronaviruses, representing potentially
difficult to overcome obstacles to safe, effective vaccine development for COVID-19,
and outline how trained immunity could help protect high risk populations through
immunomodulation with BCG and other “new old friends.”
Keywords: COVID-19, SARS, dysfunctional immune response, vaccine, trained immunity, BCG, IMM-101,
Mycobacterium obuense
INTRODUCTION
In recent months, a novel severe acute respiratory syndrome (SARS) coronavirus (CoV), SARS-
CoV-2, which causes COVID-19, has spread rapidly throughout the world (1). As of July 15, 2020,
more than 13 million infections and over 575,000 COVID-19 related deaths have been confirmed
worldwide. Based on a chronic lack of adequate testing capabilities in many countries worldwide,
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including large industrialized nations like the United States,
a large amount of undiagnosed infection and mortality from
COVID-19 must be assumed. The unprecedented pandemic
seriously challenges the world’s health care systems and available
hospital capacities to treat seriously ill patients. These challenges
are amplified by frequent SARS-CoV-2 infection of healthcare
workers (HCW), leading to hospital-acquired infection of
HCW and patients, and significant mortality within that
group (2). Other high-risk groups of infection include the
elderly, with age-related immunosenescence and “inflammaging”
having been suggested as a mechanism responsible for lowered
immunological competence and the high mortality of the elderly
in the current COVID-19 pandemic (3). Age-related risks are
a particular issue in assisted care facilities and individuals
with serious, non-COVID underlying health conditions like
cardiovascular disease, chronic kidney disease, diabetes, chronic
respiratory disease, immunosuppression, and cancer (4, 5). In
the case of cancer, many malignancies require active treatment,
making isolation – even social distancing – impossible, based
on the need to commute to the hospital regularly to receive
treatments. Therefore, there is an urgent need to protect
individuals aged 55 years and older with co-morbidities.
Throughout the public discourse, there has been little attention
given to the observations that these populations are historically
the same populations that are most unlikely to develop efficient
and protective immune responses to standard respiratory viruses.
Consequently, this is likely to be the same case for SARS-CoV-
2. Indeed, for these populations, other more potent vaccines,
compared to the general population, are required, e.g., “high
dose” Influenza shots for the elderly. Nevertheless, those more
potent vaccines often still result in less than ideal outcomes in
these vulnerable populations (6). In order to avoid the need
for achieving herd immunity by infection or mass vaccinations
before safely reopening societies and economies, a priority would
be immunizing the most at-risk populations first. There is a
justified concern that suboptimal vaccine efficacy for at-risk
populations and the elderly could place the goal of not having
to achieve herd immunity first in jeopardy. At the same time, a
non-efficacious vaccine for at-risk populations could increase the
probability of second and subsequent waves of infection in these
populations (7).
Worldwide availability of safe, effective, prophylactic vaccines
is likely the only approach that will ultimately control this
deadly pandemic. However, such vaccines may not be available
until early next year, even in the most optimistic scenarios (8).
Despite numerous efforts, no vaccine, proven safe and effective
in humans, has ever been developed against any coronavirus
(9, 10). Questions about the potential lack of sufficient vaccine
efficacy in elderly populations have not yet been widely discussed.
Therefore, strategies to prevent COVID-19 morbidity and
mortality in high risk groups are desperately needed in order to
safeguard the most vulnerable individuals, as well as maintaining
continuous patient care and functioning hospital systems.
Both humans and animals are susceptible to disease caused
by CoVs. Three highly pathogenic CoVs are known, SARS-CoV,
Middle East respiratory syndrome (MERS)-CoV and SARS-CoV-
2. All three are now known to efficiently infect and replicate
in the lower respiratory tract, frequently causing substantial
immunopathology, acute lung injury (ALI), acute respiratory
distress syndrome (ARDS), and fatal pneumonia, resulting in
high morbidity and mortality (11). SARS-CoV and SARS-CoV-
2 are both members of the betacoronavirus genus and share more
than 70% of their genetic code (12). However, it is noteworthy
that SARS-CoV-2 is closest related to the bat coronavirus
RaTG13, with 98% genetic similarity compared to all known
genetic coronavirus sequences (13). Four additional, circulating
but low pathogenic human coronaviruses (HCoV) are known
and will not be reviewed here, but preexposure to them could
impact the immune response to SARS-CoV-2 in patients (14).
All four, HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-
HKU1, display a winter seasonality, causing comparatively mild
to moderate upper respiratory illnesses and only occasionally,
bronchiolitis and pneumonia symptoms (15, 16). All HCoVs
share a minimum of four, genome encoded, major structural
proteins: the spike (S) glycoprotein, nucleocapsid (N) protein,
membrane protein (M), and the envelope protein (E), all of which
are required to produce a structurally complete viral particle (17).
IMMUNE RESPONSES TO
CORONAVIRUSES
The pandemic, which originally emerged from Wuhan, China,
has been characterized by a rapidly increasing morbidity and
mortality rate associated with older age, beginning around age
50 years (18). Multiple aspects of immunity can be influenced
by ageing, prompting scrutiny of which components of the
immune response might be responsible for higher mortality in
older people (19). In general, an early and robust innate immune
response to viral infections permits more rapid and effective
viral clearance and may even prevent symptomatic infection
or diminish the severity of the infection (20). No correlates of
protection have yet been formally established for the recently
emerged SARS-CoV-2. However, mouse model data from studies
with the first SARS-CoV that emerged in 2002, suggested a
delayed innate immune response during infection is linked to
a more severe course, with immunopathology in the lungs and
high mortality (21). Initial observational studies suggest that a
failure of antiviral immunity, including depleted natural killer
(NK) cells, at an early stage in COVID-19, may lead to severe
clinical course and an inability to recover from infection (22).
In addition, it has previously been shown that the SARS-CoV
macrodomain suppresses the innate immune response during
infection, whereas an early strong innate immune response
can protect mice from lethal disease and prevent detrimental
downstream effects on the immune system (23). On the other
hand, in later stages of infection, it appears that a dysregulated
immune system, including excessive inflammatory responses by
innate cells in the lungs, and selective immunosuppression of
the adaptive immune system, can be detrimental for the host
(24, 25). Acute lung injury caused by viruses like respiratory
syncytial virus, influenza A virus and SARS-CoV have been
described previously (11, 26, 27). Aberrant expression of the
antiviral cytokine type I interferon (IFN), interferon stimulated
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genes, and other inflammatory cytokines, were observed in
patients with severe SARS-CoV disease compared to healthy
individuals, providing evidence that SARS-CoV is partly an
innate dysregulated immune disease (28, 29).
The innate immune system recognizes pathogen-associated
molecular patterns (PAMPs) of viral or bacterial intruders via
pattern recognition receptors (PRRs). Toll-like receptors (TLRs),
a family of type I transmembrane PRRs that consists of related,
transmembrane proteins, play a central role in the initiation
of inflammatory responses against pathogens, including the
secretion of cytokines and chemokines. TLR4 is known to
sense lipopolysaccharide (LPS) from gram-negative bacteria, but,
based on its additional function as sensor for damage-associated
molecular patterns (DAMPs), TLR4 has been suggested to play a
central role in the induction of damaging inflammatory responses
during several acute viral infections (30). In addition, oxidized
phospholipids (OxPLs), DAMPs which lead to ALI in patients
infected with SARS-CoV, also accumulate in lungs of patients
infected with SARS-CoV-2 and activate monocyte-derived
macrophages through TLR4 (31, 32). Interfering with innate
cell activation by TLR4 in response to ligands such as OxPLs
may therefore help prevent thrombotic complications, recently
identified as a major factor in mortality of COVID-19 patients
(33–35). Endothelial cell activation, infection and dysfunction
has been implicated in severe COVID-19 by altering vessel barrier
integrity, promoting a pro-coagulative state, inducing vascular
inflammation, endotheliitis, and mediating inflammatory cell
infiltration. The proposed mechanism is disruption of vascular
integrity and endothelial cell death, which leads to exposure of the
thrombogenic basement membrane and results in the activation
of the clotting cascade (36). Altered platelet gene expression and
functional responses in patients infected with SARS-CoV-2 may
additionally contribute to observed hemostatic abnormalities like
disseminated intravascular coagulopathy (37).
Neutrophils
Neutrophils are an important component of the general response
to infection in the respiratory system and capable of recognizing
viruses via viral PAMPs (38). In the context of potentially
excessive neutrophil activation in late stage COVID-19 disease,
neutrophil extracellular traps (NETs) in the lungs can drive
severe pathologies by accumulation of mucus in the airways
of patients, contributing to ARDS (39). More importantly,
NETs have been proposed to contribute to organ damage and
mortality, since excess NET formation can trigger a cascade
of inflammatory reactions that destroys surrounding tissues
and facilitates atherosclerosis, aortic aneurysms, as well as
thrombosis, including microthrombosis, in the vascular system,
with devastating effects on organ function (39).
Macrophages
Macrophages are key innate immune cells in any infection
setting (40, 41). They are highly flexible innate cells that
can, simplistically, be functionally and phenotypically divided
into pro-inflammatory “M1” macrophages (capable producers
of inflammatory cytokines and mediators, that kill infectious
organisms, virus-infected cells, or tumor cells) and more
regulatory “M2” macrophages (that are important for wound
healing and parasite infections) (42, 43). Both activation states
are needed for a “balanced” immune response, although the
M1/M2 paradigm of macrophage activation is an over-simplistic
definition of these complex and diverse innate cells (44, 45).
During ageing and chronic inflammatory diseases, macrophages
may switch to a more M2-like phenotype (46, 47). Importantly,
nearly all identified high-risk factors for severe COVID-
19 disease, like cardiovascular disease, diabetes, age, chronic
obstructive pulmonary disease, and smoking, generally share a
shift from more M1 to more M2 phenotype and function (48).
Classical activation of M1 macrophages is induced by LPS/IFN-
γ exposure, while alternately activated M2 macrophages are
stimulated by IL-4, IL-10, IL-13 and glucocorticoids (49). The
activation of innate immune cells such as macrophages can be
heavily influenced by the character of the T cell response and,
in particular, the cytokines produced by T cells during infection
(50). SARS-CoV replication has previously been shown in human
peripheral monocytes and macrophages, with varying efficacy.
Importantly, the infection efficiency was shown to be donor
dependent, with 100% infection in some and less than 5% in
others (51).
γδ-T Cells
In adults, Vγ9Vδ2 cells are the dominant γδ T cell population,
however, in elderly individuals the variability increases (52,
53). An analysis of T cell repertoires in HCW who survived
SARS-CoV infection during the 2003 outbreak revealed that
an innate-like subpopulation of effector memory T cells, γδ-
T cells, specifically Vγ9Vδ2 T cells, were selectively expanded
approximately 3 months after the onset of disease (54).
Importantly, no such expansion of non-innate αβ T cells was
detected at the same time point. Furthermore, expansion of
the Vγ9Vδ2 T cell population was associated with higher anti-
CoV IgG titers, and in vitro experiments demonstrated that
Vγ9Vδ2 T cells display an IFN-γ -dependent ability to directly
kill CoV infected target cells. Therefore, innate-like Vγ9Vδ2 T
cells may play a protective role during SARS-CoV and other CoV
infections. A recent study analyzed the number and activation
status of Vγ9Vδ2 T cells in hospitalized patients with COVID-19.
They found significantly lower levels of Vγ9Vδ2 T cells than that
of matched healthy control and concluded that this could indicate
that elderly with lower frequencies of Vγ9Vδ2 T cells constitute
a SARS-CoV-2 vulnerable population or that the Vγ9Vδ2 T cells
in these patients have migrated to the lungs to kill SARS-CoV-2
infected cells (55).
T Cells and NK Cells
SARS-CoV infection leads to lymphopenia and strongly reduced
peripheral T cell levels, with low CD4+ and CD8+ T cell counts
associated with adverse outcome, and a rapid and dramatic
restoration of peripheral T cell subsets in the periphery of
recovering patients (56–58). In addition, SARS-CoV can infect
and replicate within PBMCs of SARS-CoV patients, with viral
replication appearing to be self-limiting but leading to leukopenia
or lymphopenia (59–61). Patients with clinical symptoms of
severe COVID-19 also commonly present with lymphopenia,
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including dramatically reduced numbers of NK cells, CD4+ T
cells, CD8+ T cells and B cells, which has not been observed
in mild cases (62–65). Further studies have shown exhaustion
markers like NKG2A on cytotoxic lymphocytes, including NK
cells and CD8+ T cells, are upregulated in patients with COVID-
19, and that for recovered patients, numbers of NK cells,
CD4+ T cells, CD8+ T cells, and B cells normalize, along
with markers of exhaustion on cytotoxic lymphocytes (66, 67).
Reduced functional diversity and increased T cell exhaustion in
peripheral blood could predict severe progression in COVID-19
patients, supporting the role of functional T cells in controlling
COVID-19 (67). Importantly, it was recently shown that a patient
with mild to moderate COVID-19 symptoms had a broad-based
robust immune response across different immune cell types,
which was associated with rapid recovery (68). This observational
study identified the presence of activated CD4+ T cells, CD8+
T cells, and follicular helper T cells in the blood, along with
increased antibody-secreting cells and IgM and IgG antibodies.
The study did not investigate the neutralization capabilities of
the observed antibodies. Cell-mediated type 1 immune responses
are therefore theorized to be a major component necessary to
overcome COVID-19 infection (69).
This is further supported by a study that screened for
the presence of SARS-specific T cells in a cohort of three
SARS-CoV-recovered individuals, where CD8+ T cell responses
targeting the SARS-CoV membrane and nucleocapsid proteins
were found to persist up to 11 years post-infection (70).
Characterization of SARS-CoV-specific memory T cells from
recovered individuals 4 years after infection indicated that the
majority of memory CD8+ T cells produced IFN-γ, whereas
memory CD4+ T cells produced IFN-γ, IL-2, or TNF-α (71).
Multiple other independent studies established that SARS-CoV
specific memory CD4+ and CD8+ T cells persisted for up to
2 years after infection (72–74). S protein-derived epitopes of
SARS-CoV elicited recall CD8+ T cell secretion of IFN-γ as
well as intracellular production of IFN-γ, TNF-α, perforin, and
granzyme A from recovered patients over 1-year post infection,
indicating that SARS-CoV infection can induce strong and long-
lasting cytotoxic T lymphocyte (CTL)-mediated immunity in
patients (75, 76). High frequencies of CD8+ Tc1-type T cells,
reactive against MERS-CoV, were observed in a large proportion
of patients with severe and moderate MERS at acute stage before
detection of humoral and CD4+ T cell responses. Another report
emphasizing the importance of T cells demonstrated that 17 years
after the 2003 SARS outbreak, SARS-CoV-recovered patients still
maintained long-lasting memory T cells reactive to the N protein
of SARS-CoV, which notably exhibited robust cross-reactivity
to the N protein of SARS-CoV-2 (77). A recent study showed
predominant Th1 responses in convalescing COVID-19 cases,
with little to no Th2 responses. It demonstrated SARS-CoV-
2 specific CD4+ T cells in 100% of COVID-19 convalescent
patients, with the majority of responses against S protein,
correlating with the magnitude of anti-SARS-CoV-2 IgG and
IgA titers, but as well responses against M and N proteins in all
patients, accounting for 11–27% of the total CD4 + responses.
The same study found SARS-CoV-2 specific CD8+ cells against
S and M proteins in about 70% of patients, and interestingly, T
cell reactivity to SARS-CoV-2 epitopes was also detected in non-
exposed individuals, likely cross-reactive from previous, seasonal
HCoV infections (78). However, at the convalescent phase, the
magnitude of the CD8+ T cell response was not increased further.
Although it seems clear that robust inflammatory and CTL
responses are required to clear the invading virus, when excessive,
they can also lead to lung tissue destruction and pneumonia (79).
Early pathological findings of COVID-19 patients with ARDS,
showed not only reduced counts of peripheral CD4+ and
CD8+ T cells, but that remaining T cells were found in a
hyperactivated state, with high proportions of HLA-DR and
CD38 double-positive fractions (80). It is noteworthy here that, in
patients hospitalized with avian H7N9, survival reflected an early,
but transient, prevalence of highly activated CD8+CD38+HLA-
DR+PD-1+ T cells, but prolonged CD38+HLA-DR+PD1+ co-
expression predicted fatal outcomes (81). CD8+ T cells in patients
that died of H7N9 were non-functional, as reflected by a lack of
IFNγ production, but displayed high and continued expression
of the CD38+HLA-DR+ activation markers, together with the
inhibitory PD-1 immune checkpoint receptor. Similar studies
in Ebola, Dengue, and pandemic H1N1 have also mentioned
the presence of these “non-survival” peripheral lymphocyte
populations, with high and prolonged frequency of activated
CD8+CD38+HLA-DR+ cells (82–84). We hypothesize that, as
suggested for H7N9 disease (81), in COVID-19 patients this
could also be associated with defective T cell activation and a lack
of relevant T cell receptor (TCR) specificities. It is known that
infection with human immunodeficiency virus (HIV) induces
broad lymphocyte activation, with an increase in T cell activation
markers such as CD38 (85). Several studies have shown that
such increased CD38+ expression on CD8+ T cells is a strong
predictive marker for disease progression in HIV-1 infection (86).
Not only does the CD8+CD38+ T cell count predict progression
of HIV disease to AIDS and death, but it is also independently
predictive for evaluation of high plasma virus load and low
CD4+ T cell counts (87). In early HIV infection, during onset
of viremia, CD8+CD38+HLA-DR+ T cells correlate inversely
with viral set point. However, hyperacute HIV infection leads
these cells to be short-lived effector cells that do not persist,
characterized by marked apoptosis, upregulation of CD95 and
failure to upregulate the IL-7 receptor CD127 (88). Strikingly, in
a recent study in COVID-19 patients, considerable proportions
of peripheral CD4+ and CD8+ T cells co-expressed CD38 and
HLA-DR, but those cells could not be re-activated with peptide
pools of the S protein in vitro, supporting the notion of SARS-
CoV-2 specific refractory T cells and/or different specificities
(14). No data about the PD-1 status of T cells was provided.
The same remarkable study showed that, while the majority of
S-reactive CD4+ T cells from COVID-19 patients co-expressed
CD38 and HLA-DR, S-reactive CD4+ T cells from healthy
donors, proposed to be cross reactive to other HCoVs, only
expressed CD38 and HLA-DR at very low frequencies and co-
expression was not observed. In cancer therapy models, depleting
“dysfunctional” CD8+CD38hiPD-1+ cells enhanced therapeutic
outcomes, and patients who did not respond to immunotherapy
showed more CD8+CD38hiPD-1+ in tumor and blood compared
to responders (89). The potential significance of levels and
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timing of prolonged expression of CD38, HLA-DR, and PD-1
on dysregulated T cells and the utility of CD8+CD38+HLA-
DR+PD-1+ T cells as a prognostic marker could be important
and should be investigated in more detail. These could serve
as indicators of SARS-CoV-2 immunosuppression, exhaustion
and immune evasion, predicting divergent disease outcomes.
The suggestion that a dysfunctional immune response is at
the heart of COVID-19 pathology is further supported by the
recent finding that, compared to patients with moderate disease,
significantly reduced frequencies of CD8+ T cells, as well as
diminished frequencies of CD4+ and CD8+ T cell subsets
with activated differentiated memory/effector phenotype and
migratory capacity, are found in peripheral circulation of patients
with severe COVID-19 (90).
B Cells and Antibodies
Antibody responses elicited by coronaviruses, including SARS,
have been described as comparatively short lived and inconsistent
(91, 92). Studies with human volunteers that were infected with a
seasonal coronavirus HCoV-229E showed that individuals could
get infected and display symptoms, including lymphocytopenia,
regardless of preexisting antibodies (91). One study showed that
six years post infection, SARS-CoV specific IgG was undetectable
in 21 of 23 former patients, and no SARS-CoV specific memory
B cell responses could be detected in any of the 23 patients (93).
Another study revealed that SARS-CoV antibodies could be seen
up to 24 months after infection (93). Interestingly, longevity of
MERS-CoV antibody response correlated with disease severity.
In one study, patients with severe MERS-associated pneumonia
had a persistent antibody response detected for about 18 months
after infection, while patients with infection limited to the
upper respiratory tract or who had no clinical signs had no
detectable MERS-CoV antibody response (94). In another report,
the more severe the illness, the greater the antibody response,
including IgM, IgG, and neutralizing Ab (NAbs). Patients in
the convalescent phase, with mild or asymptomatic disease,
rarely developed antibody responses (79). A strong antibody
response developed in most MERS patients only after 2–3 weeks
of illness, but the antibody responses were not correlated with
the elimination of the virus from the body (95, 96). This was
confirmed in two more studies that showed MERS infections are
frequently characterized by low NAbs, despite patient recovery
(93, 97–99). It is noteworthy that this was also recently shown for
COVID-19 patients, where seroconversion has been observed in
9 mild to moderate cases after 6–12 days, but, despite COVID-
19 antibodies arising at that time, no rapid decline of viral loads
was observed, as would be expected with highly effective and
neutralizing antibodies (100). Since anti-SARS-CoV antibody
responses are short-lived in patients who have recovered from
SARS, there are early indications that antibodies, and especially
NAbs, may not be the predominant mechanism necessary for
effective viral clearance and for infected individuals to overcome a
COVID-19 infection (10, 101–103). This is further reinforced by
the first longitudinal study in COVID-19 patients, which showed
that some individuals who have recovered and displayed a strong
NAb response shortly after infection, had titers fall as much as
23-fold, and in some cases back to baseline within 3 months
(104). The authors speculated that the observed transient NAb
response could be a feature shared by both a SARS-CoV-2
infection that causes low disease severity, and the circulating
seasonal coronaviruses. Other recent data supports the notion
of an unclear role of Abs, by reporting short duration of Ab
and NAb titers after SARS-CoV-2 infection. Compared with
responses of patients with symptoms, asymptomatic individuals
(arguably with the more effective immune response), had weaker
Ab responses to infection, with a reduction of IgG levels already
occurring in the early convalescent phase (105); viral load and
duration of infection are likely to be factors. Remarkably, in
this study, 40% of asymptomatic patients had undetectable levels
of protective antibodies two to three months after infection,
compared to 13% of the symptomatic patients with COVID-19.
An even more notable finding, further indicating a limited role
for Abs in overcoming SARS-CoV-2 infection, is that intrafamilial
exposure to SARS-CoV-2 induces a cellular immune response
without seroconversion (106).
SARS Vaccine Challenges
Of the different proteins that characterize coronaviruses, the S
protein is an important determinant of virulence, tissue tropism
and host range (107). Trimers of S form the characteristic
large spikes on the coronavirus envelope and both SARS-
CoV and SARS-CoV-2 use the protein angiotensin converting
enzyme 2 (ACE-2) as primary receptor for docking and infecting
human host cells. Priming of the virus S protein by host cell
proteases is essential for entry. When SARS-CoV-2 docks to
the cell via the ACE-2 receptor, the host transmembrane serine
protease 2 (TMPRSS2) is responsible for cell entry (108–110).
TMPRSS2 also aids the MERS-CoV to penetrate the cell (111),
but its primary receptor for entry is dipeptidyl peptidase 4
(DPP4) (112). Virus S glycoproteins are postulated to elicit an
immune response in humans that could protect against future
infection (108, 113). Many vaccine approaches against COVID-
19 that are currently in development are focusing primarily
on the generation of antibody responses against the SARS-
CoV-2 S protein (8). However, despite the great urgency for
making an effective vaccine against COVID-19 available, this
approach must be undertaken with great caution. Several SARS-
CoV vaccines that initially induced antibodies and short-term
protection in mouse models of SARS-CoV led to dysfunctional or
type 2 helper T cell (Th2)-type immunopathology on challenge,
with prominent eosinophil infiltration in the lungs, suggesting
hypersensitivity to SARS-CoV components was induced (10).
Several other independent studies with animal models used to
develop vaccine candidates against SARS-CoV exposed signs
of lethal vaccine failure based on induction of cell-mediated
type 2 enhanced immunopathology, with associated eosinophilic
infiltrates causing severe pneumonia, especially in aged mice.
A vaccine based on SARS-CoV S protein protected against viral
challenge when young mice were vaccinated, but it failed to
efficiently protect older mice (114). Another study indicated
poor vaccine performance as well as Th2-based eosinophilic
immune pathology in the lungs that was shown to be caused
by alum adjuvanted and unadjuvanted SARS-CoV vaccines in
aged animals (115). All this requires that particular attention be
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given to the strongly increased mortality rate already evident
in older SARS-CoV-2 patients and patients with comorbidities.
SARS-CoV has been shown to dysregulate the immune response
in SARS patients by biased activation of a Th2 response, which
can counter-regulate the type 1 response that normally attacks
bacteria and viruses (97). There was a significant increase in Th2
cytokines IL-4, IL-5 and IL-10 during acute infection in fatal
SARS cases, once again indicating that the character of cellular
immune response induced by any COVID-19 vaccine will be
critical in determining whether it will succeed (101, 116). Four
earlier vaccines against MERS-CoV-2 have been tested in rhesus
macaques (RM), but no reports of efficacy of a single-dose MERS-
CoV vaccine in non-human primates (NHPs) had been made
until a recent study reported that RM seroconverted after a single
intramuscular vaccination with the experimental ChAdOx1
MERS vaccine (117). The study showed that vaccinated animals
developed a neutralizing antibody response, were protected
against respiratory injury and pneumonia, and showed reduced
viral load in lung tissue and reduced disease severity. In addition,
a Phase 1 trial in healthy individuals aged 18–50 years has
been conducted, with no adverse safety signal reported (118).
Neither study has provided data in either aged animals or elderly
humans. Most relevant in this context are early SARS-CoV-
2 vaccine trial data. A Phase 1/2 study in adults aged 18 to
55 years of a COVID-19 RNA vaccine candidate (BNT162b1),
utilizing mRNA that encodes trimerized SARS-CoV-2 spike
glycoprotein, showed the generation of NAb titers 28 days after
the first injection and one week after the second dose (119). It
is not yet known what kind of immune response the vaccine
will elicit in older people or long-term. An additional mRNA
nano-particle based vaccine candidate (mRNA-1273) has been
reported to induce both potent Nabs and CD8+ T cell responses
and to protect against SARS-CoV-2 infection in the lungs and
noses of a mouse model, without evidence of immunopathology
(120). Importantly, it showed spike peptide-reactive CD4+ and
CD8+ T cells producing IFN-γ, IL-2, and TNF, which would be
encouraging if corroborated in ongoing Phase 2 clinical trials
and Phase 3 efficacy evaluation of the same vaccine candidate.
Another advanced SARS-CoV-2 vaccine candidate in Phase 1
clinical studies is adenovirus-vectored vaccine ChAdOx1 nCoV-
19, which has been reported to prevent SARS-CoV-2 pneumonia
in RM and not to be Th2 dominated, determined by IgG subclass
and cytokine expression profiling (121). Notably, no evidence of
immune-enhanced disease following viral challenge twenty-eight
days after vaccination was observed in the respective animals. The
levels of Abs produced by the vaccine in these RM were lower
than many Ab responses in humans infected with SARS-CoV-
2. While the vaccine protected RM from severe infection, they
became infected with evident active virus replication, which does
not rule out the potential of maintained ability to transmit virus.
Despite the inherent challenges of adopting new routes of
routine vaccine administration during an ongoing pandemic,
recent evidence would encourage consideration of intranasal
administration, inhalation or other vaccine strategies that
directly target the mucosal surfaces of the airways, because
of distinct functional responses by respective tissue-resident
memory T cells (122). It was shown, for example, in a mouse
model, that conserved epitopes shared by SARS-CoV and MERS-
CoV could induce airway memory CD4+ T cells producing
IFN-γ which were phenotypically and functionally different from
lung-derived cells and crucial for protection against both CoVs.
It is particularly noteworthy in this study that intranasal (but
not subcutaneous) vaccination protected mice from pathogenic
human CoVs, and that protection required IFN-γ and was
depended on early induction of robust innate and virus-specific
CD8+ T cells (123).
SARS-CoV-2 has shown replication, not only in human
peripheral monocytes and macrophages, but also to directly
infect T lymphocytes during primary infection through S protein-
mediated membrane fusion, likely contributing to the severe
lymphocytopenia that is a diagnostic indicator common in
COVID-19 patients (51, 100, 124). SARS-CoV has also been
shown to infect dendritic cells (DC), the central coordinators of
the immune response, leading to impaired DC maturation and
their high expression of the pro-apoptotic protein TRAIL (125).
Instead of facilitating lymphocyte activation and expansion in
numbers, this likely induces lymphocyte death and represents
another mechanism of immune escape and intensification of the
immunocompromised state of SARS-CoV patients (126). Similar
mechanisms could contribute to lymphopenia and dysfunctional
immune responses observed in severe COVID-19 patients. In the
elderly, immune evasion by SARS-CoV-2 is probably made worse
due to the reduced number and function of antigen presenting
cells (APCs) (127). Multiple studies have been performed in
mouse models describing the importance of type 1 CD4+
and CD8+ T cells in SARS-CoV (128, 129), with one study
establishing that virus-specific memory CD8+ T cells provided
substantial protection from lethal closely related SARS-CoV
infection in a mouse model, emphasizing the importance of
a cell-based type 1 immune response for survival of SARS
infections (102). The majority of the many current vaccine
strategies against SARS-CoV-2 rely on unadjuvanted or self-
adjuvanted vaccines (e.g., RNA and DNA vaccines), or type 2
immune response promoting vaccines (e.g., alum adjuvanted, or
unadjuvanted peptide or protein based vaccines) (113, 130, 131).
Rather than promoting type 1 immunity, such approaches are
likely to mostly lead to induction of type 2 responses which,
as previously discussed, are unlikely to be effective against
SARS-CoV-2 (100). Existing CoV antibodies have, in the case
of host challenge with the same virus, enhanced viral load
and disease severity in feline coronavirus or feline infectious
peritonitis virus (FIPV) infections. This phenomenon is known as
antibody-dependent enhancement (ADE) of viral infection (132,
133). In FIPV infection ADE can be induced by the presence
of sub-neutralizing levels of anti-FIPV spike antibodies (134).
Unlike in dengue virus infections, ADE in feline coronavirus
infection is caused by re-infection with the identical serotype
virus (124). It should be noted that mice, often used for
preclinical safety evaluation of vaccines, lack FcγRIIa, the main
FcγR on human cells linked to ADE induction (135, 136).
Increasing viral entry into permissive cells and/or triggering
excessive production of pro-inflammatory cytokines has made
ADE a significant concern with several viruses, including the
closely related SARS-CoV (137, 138). Concerns have also been
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raised that anti-SARS-CoV-2 non-neutralizing antibodies, or
even declining NAb titers over time, could lead to ADE and
enhanced disease after such vaccinations, antibody-based drug
therapies, or treatment with convalescent plasma from recovered
patients (139, 140). However, none of the early clinical trial results
of the most advanced vaccine candidates described above have
reported signs of ADE (121). Demonstration of a lack of ADE
induction of different experimental vaccines against SARS-CoV-
2 in NHPs and humans will remain critical for other vaccines
advancing through the pipeline. One recent example of the
need for continued vigilance is a study using Chinese macaques
indicating cause for concern by showing that vaccine-induced,
S-specific immunity in the form of anti-spike IgG resulted in
severe ALI by skewing macrophage responses during subsequent,
acute infection with closely related SARS-CoV (139).
Given all of the above, it is likely that successful vaccines
against COVID-19 will require appropriate DC activation,
leading to induction of a multifaceted and long-lived type
1 immune response that includes memory CD4+ Th1 cells,
CD8+ CTLs, and NAbs. Most importantly, they will need to be
effectively induced and sustained in older individuals without
generating type 2 responses or ADE. It may remain a challenge
to achieve this formidable goal and more creative approaches
to vaccination may be required, but early data from pre-clinical
and clinical trials of SARS-CoV-2 vaccines seem encouraging that
they will provide some protection.
Cytokine Storm
Direct comparisons in the literature of clinical observations
in COVID-19 patients with IL-6 induced “cytokine storm”
or cytokine release syndrome (CRS) should be made with
caution (25, 141, 142). For example, cytokine levels during
hyperinflammation in COVID-19 are multiple orders of
magnitude lower than has been observed during cancer
treatments by adoptive cell transfer of autologous T cells
modified with chimeric antigen receptors (CAR-T cell therapy),
a classical example for CRS (143, 144). Although, CRS is
normally treated with extensive use of steroids, the clinical
evidence does not support corticosteroid treatment for COVID-
19 induced lung injury and interfered with clearance (145). In
SARS and MERS, corticosteroid use did not improve patient
mortality and also resulted in delayed viral clearance (11).
It should be noted that a recent preprint of a randomized-
controlled trial observed that therapy with dexamethasone lead
to a significant reduction of death in ventilated patients, as well
as for patients on supplemental oxygen, while no benefit was
shown in mild cases (146). A recent review of corticosteroid
use in the management of COVID-19 revealed a mixed picture
from five available studies. In four retrospective studies and one
quasi-prospective study, three studies indicated a benefit, while
the other two studies showed no benefit, and one sub-study
even suggested significant harm in critical cases (147). Based
on success in hematological and oncology settings, several IL-6
antagonists (tocilizumab, sarilumab as well as siltuximab) have
been utilized as emergency interventions in COVID-19 patients
with ARDS and hypotension, although so far with mixed results
(148). IL-6 is an indispensable cytokine that initiates innate
defence after pathogen invasion or tissue damage by stimulating
acute phase reactions, immune responses, hematopoiesis, and
activation of numerous internal organs to prepare for host
defence (149). Therefore, IL-6 and other cytokines like tumor
necrosis factor (TNF)-α are indispensable during functional
activation of monocytes, macrophages and DCs before or early
during COVID-19 disease, as they are in diseases caused
by other respiratory viruses (150). However, in later disease
stages increasing immune dysregulation and T cell apoptosis,
macrophages and IL-6 may accelerate immune imbalance (151).
Preventing and treating coronavirus infections will likely
need a multiphasic approach to prophylaxis and therapy,
especially in vulnerable populations. It will be important to
use the right tools at the right time to avoid unintended and
potentially counterproductive consequences. The right set of
immunomodulators would likely be able to prepare and boost
innate immune defences to either ensure appropriate, effective
responses to infection and/or guide the development of suitable,
protective immunity in response to potentially suboptimal
adjuvanted first generation vaccines. Antiviral treatments or
combinations of them will be most useful during early infection,
while a different set of immunomodulators may be needed in late
stage and severe disease, where a dysregulated antiviral response
can cause deadly collateral damage.
MICROBIAL “OLD FRIENDS” AND BCG
Some microbes have existed throughout human history, with
evidence of their presence in hunter-gatherer societies, shaping
the evolution of the human immune system (152). Some of
these microbes, branded as “old friends” or “old infections,”
are thought to be so intricately involved in this process
that they are required for human immunity to develop and
function properly (153, 154). Examples of such microbes are
harmless mycobacteria that are present in the environment
and used to be prevalent in water and food, where they were
postulated to have a “training” impact on the human immune
system (153). In addition, “paleolithic” strains of Mycobacterium
tuberculosis (Mtb) that were less pathogenic than modern strains
could have contributed to this process (152). Environmental
Mycobacteria can provoke type 1 responses, as has been shown
in mouse models and human cell-based in vitro studies for
heat killed Mycobacterium obuense, NCTC13365 (IMM-101) and
Mycobacterium vaccae, NCTC11659 (IMM-201) (155–158). This
is also the case for the attenuated strain of Mycobacterium bovis,
BCG (159). However, modern, urban societies are often missing
frequent exposure to environmental bacteria such as M. obuense
and M. vaccae – they literally have lost touch with their “old
friends” and may need “new old friends,” to support type 1
immune responses.
Remarkably, several observational studies have recently
proposed that countries with active BCG vaccination in
place had fewer confirmed COVID-19 cases and related
deaths (160–162). These observational studies should be
appraised with caution, since there are many confounding
factors in interpreting such correlative data in the context
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during the COVID-19 pandemic (163). There is no peer-
reviewed data yet, or a clear scientific hypothesis about the
proposed mechanism of action, to explain how decades
later a single BCG vaccination could provide long lasting,
heterologous protection against a viral disease. In contrast,
there are evidence-based arguments, acutely relevant to
the COVD-19 pandemic, regarding how BCG or type 1
immune inducing environmental Mycobacteria could provide
protection against severe COVID-19 in the form of the trained
immunity hypothesis.
TRAINED IMMUNITY UTILITY FOR
VACCINES
Contact with specific microbial stimuli can induce long-lasting
epigenetic changes in innate immune cells, which not only
results in an enhanced response to a second challenge by the
same microbe, but also to unrelated microbial insults (164).
Referred to as “trained” immunity or innate immune memory,
this process was originally shown for the BCG vaccine (165,
166). This concept may help explain previous observations
that, after infection or vaccination, prototypical innate immune
cells like monocytes, macrophages and NK cells undergo long-
term changes in their functional programs, promoting host
resistance against a wide spectrum of pathogens, including fungi,
bacteria and viruses (167). Trained immunity is thought to be
responsible for the observation in clinical studies that childhood
vaccination with BCG correlates with protection against 30–
50% of infections with any known pathogen, including viruses
(168, 169). Additionally, a reduction in childhood mortality,
unrelated to the prevention of tuberculosis (TB), has been
observed (169). Similar positive effects have been shown for
BCG vaccinations in adults, including improving responses to
Influenza vaccination (170). A study in Guinea-Bissau showed
that BCG reduced the incidence of respiratory syncytial virus
infection (171). Importantly for the at-risk populations for severe
COVID-19, it was shown that BCG had a similar protective
effect on respiratory tract infections in older individuals in
Indonesia (172). In addition, a clinical trial performed in older
individuals in Japan established protection against pneumonia
after pneumococcal, influenza and BCG vaccinations (173).
Further confirmation of this effect has been demonstrated in a
randomized controlled trial in which BCG vaccination protected
against experimental infection of a yellow fever virus (174).
In summary, BCG vaccination has been shown to protect
against a range of viral infections (175). Related to this, when
vaccination against smallpox was introduced around 200 years
ago, positive side-effects such as protection against measles,
scarlet fever and whooping cough, among others, were noticed
(176).
Monocytes from healthy human volunteers were stimulated
ex vivo with unrelated pathogens and displayed enhanced pro-
inflammatory cytokine production of IL-1β, TNF and IL-6
after BCG vaccination (165). Experimental studies in mice have
delineated that some of the mechanisms by which BCG induces
these protective effects. For example, in mice, reduced viral titers
of influenza A virus rely on macrophages (177). Subcutaneous
administration in mice of muramyl dipeptide (MDP), part of
the mycobacterial cell wall, protected against vaccinia virus and
herpes simplex virus type 2 (HSV2) infections (178). Newborn
mice could be protected with BCG from infection by HSV2 (179).
More recently, other inducers of trained immunity have also
been identified, including β-glucan, which has been shown to
induce protective trained immunity in human monocytes and
against Mtb infection in mice (180). The combination of these
observations and others led to the proposal of the development
of trained immunity-based vaccines (TIbV).
TIbVs aim to induce a pre-activated or “poised” activation
state in innate immune cells. In this way they are, unlike
conventional vaccines, theoretically able to stimulate much
broader immune responses that are not focused on just one
specific pathogen (181). This capacity of TIbVs to promote
responses beyond their nominal antigens may be particularly
useful when conventional vaccines are not available, or when
multiple co-infections and/or recurrent infections arise in
susceptible individuals at the same time, as is the case in the
current pandemic COVID-19 health emergency. At least six
different countries, including the Netherlands and Australia,
have initiated clinical trials with the intent of investigating BCG
vaccination as TIbV to protect HCW from symptomatic or
serious COVID-19 infections (175, 182, 183).
In general, BCG is regarded a safe vaccine in young and
healthy individuals. However, as is the case with any vaccines
containing live attenuated organisms, there is a possibility
of adverse events, such as disseminated BCG disease, in the
elderly and immunocompromised. For this reason, in cancer
patients, who represent a high-risk group for severe COVID-
19 infection, BCG is contraindicated in several countries highly
impacted by the pandemic, including the United States and
Canada (184, 185). As a result, populations likely to benefit
most from the potential of TIbVs and at the highest risk of
a severe COVID-19 disease (e.g., cancer patients, frail elderly,
or other people with impaired immune systems), cannot be
included in BCG vaccination strategies. Despite the potential
promise for mitigation of the COVID-19 pandemic, a major
obstacle to its quick, rational deployment is the fact that the
BCG vaccine comprises of a number of genetically distinct
substrains (186). These have subsequently been shown to have
different immunological properties, such as variable virulence
and efficacy as a tuberculosis vaccine in mice (187). This substrain
diversity may also help explain some inconsistencies following
BCG use, such as variable Th1 or Th2 induction and side-effects
(188). In clinical use, no evidence was found that vaccination
efficacy against TB was associated with a specific BCG strain;
however, a Th1 or Th2 bias was not investigated in that study
(189). It has also been shown that the immune response can be
directed from Th1 to mixed Th1/Th2, depending on the dose
of BCG used (190). Bacille Calmette-Guérin is not routinely
injected more than once, but an earlier study showed that, of
six patients who were given a second inoculation of the BCG
vaccine, three showed persistent cutaneous granulomas (191).
A recent clinical study also observed evidence of a protective
effect against persistent Mtb infection after BCG revaccination
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(192); although repeat treatment with BCG has been used in
the past in oncology as an adjuvant to boost cell-based cancer
vaccines (193).
Mycobacterium obuense (IMM-101)
IMM-101 is a preparation of heat killed, whole cell, M. obuense
National Collection of Type Cultures (NCTC) 13365, one of
over 100 named species within the genus Mycobacterium, and
an “old friend.” M. obuense is a rapidly dividing mycobacterium
that normally grows as an environmental saprophyte (194). Since
IMM-101 is a heat killed preparation, treatment is not associated
with the potential side-effects of delivering live or attenuated
organisms (195). Moreover, one can speculate that IMM-101, by
virtue of its potent type 1 inducing ability, will counter-regulate
type 2 responses, helping to explain the encouraging clinical
results to date in melanoma and pancreatic cancer (195, 196).
An open label, Phase 2 study of IMM-101 in combination with
checkpoint inhibitor therapy Nivolumab is currently underway in
patients with advanced melanoma in the United Kingdom (197).
The total number of patients exposed to IMM-101 across clinical
trials and compassionate programs without any unexpected
adverse events has been over 345. The mode of action of IMM-
101 is in the process of being elucidated, but it has been shown
to be a multifaceted modulator of both innate and adaptive
arms of the immune system (158). Experiments with mouse
and human immune cells have shown that IMM-101 is very
effective in inducing cytokine expression by innate immune cells,
including M1 polarization and enhanced antigen presentation
by DCs, leading to a typical type 1-biased immune response
(Figures 1, 2) (198, 199). Systemic activation of, and IFN-
γ production by, multiple immune cell types (158), including
innate immune cells like NK cells, T cells expressing gamma/delta
receptors (γδ-T cells) and natural killer T (NKT) cells (157, 200)
(Figure 1), is based in part on the promotion and activation
of CD4+ Th1, and CD8+ CTLs, with increased production of
the cytokine IFN-γ in in vitro and in vivo (198–202). It is
also possible that, in this setting, IMM-101 may act to train
monocytes for enhanced M1 function (Figure 2). NK, γδ-T,
NKT, Th1 cells, and CTLs, are well-known to play crucial roles
in anti-viral and anti-tumor responses that can kill infected or
tumor cells. This diverse mechanism of action of IMM-101, the
safe promotion of a broad, systemic innate and adaptive type 1
immune response, may provide a rationale for considering its use
against SARS-CoV-2.
Interestingly, BCG has been shown to promote activation of
Vγ9Vδ2 T cells, the major subset of γδ T cell pool in human
peripheral blood with a previously proposed protective role
against SARS-CoV (see above) (203). Vδ2 T cells are exactly the
cell-subtype that has been shown to also be activated by IMM-
101 stimulation, in some experiments showing a stronger ability
to do so than BCG (157). γδ T cells normally only represent
a minor subset in peripheral blood, but can rapidly proliferate
following infection with certain pathogens, expanding from 1%
to over 50% of circulating T cells within a week (204, 205).
FIGURE 1 | IMM-101 induces a robust systemic type-1 biased immune response | Recognition of IMM-101 by DCs results in increased expression of co-stimulatory
molecules, enhanced antigen processing and presentation capacity and induction of an array of pro-inflammatory cytokines 156, 158, 198–202). IMM-101 activated
dendritic cells (DC) directly promote the proliferation of CD8+ cytotoxic T-lymphocytes (CTL) and type-1 polarised CD4+ T cells, whereas innate-like cells including
natural killer (NK), NKT and γδ T cells can be activated either by direct interaction with IMM-101 or indirectly via recognition of DC secreted cytokines (156, 157). This
local DC activation eventually leads to a systemic increase in immune cells secreting anti-viral interferon (IFN)-γ, perforin and granzyme B (158, 202). Th, helper T cell.
TNF, tumour necrosis factor.
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FIGURE 2 | BCG and environmental mycobacteria promote M1 macrophages and are likely to induce trained immunity. (A) Treatment with mycobacterial
immunomodulators induce polarization of M1 macrophages along with “trained” inflammatory monocytes with enhanced M1 function, which can result in enhanced
viral clearance (164–166, 199). (B) During innate immune training, innate cells undergo long-term cellular reprogramming. Unlike classical antigen-specific responses
seen with adaptive immunity, this reprogramming results in increased capacity to respond to secondary challenges from a variety of pathogens and forms the basis
of trained-immunity based vaccines (170–172, 181).
It is noteworthy that a large majority of Vδ2 T cells co-express
Vγ9 in humans, and were shown to be important to overcome
SARS-CoV infection (54, 206).
In addition to Th1 cells, CTLs and γδ T cells, NK and
NKT cells also play key protective roles during viral infection
(207, 208), and the potential importance of improving the NK
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cell and CTL response at the early stage of SARS-CoV-2 infection
has already been highlighted (22). Under the umbrella of trained
immunity, broad protection could be achieved by systemically
increasing the non-specific effector response of innate immune
cells (e.g., macrophages, NK, NKT, and γδ T cells) while also
enhancing DC activation and ability to promote adaptive T cell
(e.g. Th1 and CTL) and B cell responses to both specific and non-
related (bystander) antigens, all of which have been shown for
IMM-101 (Figure 1) (198, 199).
Several studies have shown that the effects of IMM-101 are
in part mediated by TLR2/1, and to a lesser extent, TLR2/6
(198, 199). TLR2 has been shown to directly trigger Th1 effector
functions in mice (209). Subsequently, it was shown that IMM-
101 activates human Mincle reporter cell lines (158, 227). It is
noteworthy that Mincle can suppress TLR 4 activation (211) and
TLR4 has been proposed to have a central role in the initiation
of damaging inflammatory responses during different acute viral
infections (30). In contrast to BCG, IMM-101 does not activate
TLR4 (198, 199, 212). In a similar manner, Mincle suppresses
Th17 immune responses, which as well have been suggested
in coronavirus immunopathology and vaccine-induced immune
enhancement (213, 214). It was only recently discovered that
activation of the Mincle receptor is a key activation pathway for
Complete Freund’s Adjuvant (CFA), the “gold standard” adjuvant
for eliciting cell-mediated immunity (CMI) in research models
(215–217).
Effective and enhanced viral and tumor antigen cross-
presentation requires TLR2 or TLR3 activation of human
DCs (218). Mouse CD8α+ DCs express TLR7 and TLR9, in
addition to the TLR2 family and TLR3, whereas the only
relevant corresponding cross-presenting human CD141+ DCs
in lymph nodes exclusively express the TLR2 family and
TLR3 (218, 219). Importantly, analysis of the susceptibility of
primary human DC subsets to viral infections has shown that
FIGURE 3 | BCG and “new old friends” have potential utility for prevention of severe COVID-19 in a number of ways. Bacille Calmette-Guérin (BCG) and other
mycobacterial immunomodulators initiate robust type 1 immune responses and innate immune training, leading to tissue type 1 immune cell infiltration and elevated
basal systemic type 1 inflammation (156–159, 164–166, 198–202). This allows for potential alteration of disease trajectory through prevention of viral establishment,
enhanced viral killing or as a vaccine adjuvant to enhance immunity.
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CD141+ DCs have an innate resistance to infection by a broad
range of enveloped viruses, including HIV and influenza virus.
In contrast, CD1c+ DCs are susceptible to infection, which
enables viral antigen production, but impairs their immune
function and survival. This has led to the conclusion that
inclusion of TLR2 or TLR3 agonists would be the most direct
mechanism to enable enhanced viral and tumor antigen cross-
presentation, likely necessary for effective cancer immunotherapy
(218) and viral clearance (220). Interestingly, previous work
has suggested that vaccine-induced eosinophil immunopathology
in the lungs after SARS-CoV infection could be avoided with
the use of TLR3 agonists as adjuvants (221). However, use
of TLR3 agonists may have to be viewed with caution in
the context of COVID-19, based on observations of harmful
contributions of TLR3 to influenza A virus-induced acute
pneumonia in mice. In that scenario, TLR3-influenza A virus
interaction critically contributed to the debilitating effects of a
detrimental host inflammatory response (222). Further, it has
been shown that TLR4 signaling induces TLR3 up-regulation
in alveolar macrophages during ALI, and that TLR4 and
TLR3 in macrophages are an important determinant in ALI
(223), and that there is an association between respiratory
syncytial virus TLR3-mediated immune responses and chronic
obstructive pulmonary disease exacerbation frequency (224).
TLR2 activation of macrophages leads to M1 polarization, and
a shift from M2 into M1 macrophages (225). In addition,
it has been shown that TLR2 activation of macrophages can
impair activity of M2-like macrophages (226). IMM-101 activates
TLR2 and not TLR4 and leads to M1 macrophage polarization
(Figure 2) (198, 199). The combined characteristics of IMM-101
have led to the approval by Health Canada of a randomized,
Phase 3 trial of immunization with IMM-101, versus observation,
for the prevention of severe respiratory and COVID-19 related
infections in cancer patients at increased risk of exposure (210).
DISCUSSION
In this review, we have presented an overview of current
knowledge of the innate, adaptive and dysfunctional immune
responses to SARS-CoV-2, in relation to other closely related
coronaviruses. We have outlined the responses that may be
required for successful vaccine development against COVID-
19, while highlighting potential risks during this development,
especially for the elderly. Early clinical data look promising,
but continued studies of human and NHP immune response
to different SARS-CoV-2 vaccines in the pipeline are required
to mitigate potential dangers of well-intended, but potentially
flawed, vaccines that are being expedited to large parts of high-
risk populations around the globe. In addition, the potential
utility of “new old friends” as TIbVs like BCG or heat
killed environmental bacteria such as IMM-101, that act as
multitargeted, systemic immunomodulators of the innate and
adaptive immune system have been described. Studies to show
BCG’s and IMM-101’s potential utility for the prevention of
severe COVID-19 are underway or planned, with the potential
to change immune status and alter disease trajectory in multiple
ways (Figure 3): (i) as prophylaxis, with enhanced innate memory
and increased basal systemic type 1 immunity preventing viral
establishment; (ii) as a treatment for patients in early stages of
disease, with increased local and systemic type 1 inflammation
enhancing killing of virally infected host cells; (iii) as an adjuvant
for future COVID-19 vaccines. Thus, BCG and IMM-101 have
the potential to be rapidly deployed to address the COVID-19
emergency and the challenge posed by the current lack of effective
treatments and vaccines, leading to a high unmet medical need.
With other routes of vaccine and therapy development likely to
take many months or years to develop, or even reformulate, the
help of “new old friends” such as BCG and IMM-101 may be
precisely what we need in the current pandemic crisis.
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